David Amsellem
Stock Analyst at Piper Sandler
(4.79)
# 110
Out of 5,050 analysts
159
Total ratings
65.08%
Success rate
23.51%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $6.04 | +32.45% | 2 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $219.16 | +31.87% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $31.34 | +30.82% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $11.37 | +14.34% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $152.37 | +17.48% | 12 | Oct 29, 2025 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $45 | $32.89 | +36.82% | 8 | Oct 23, 2025 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Overweight | $40 → $65 | $46.02 | +41.24% | 17 | Oct 9, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $320.20 | +6.81% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $155.51 | -24.12% | 2 | Aug 14, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $24.03 | +4.04% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $73.72 | +64.13% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.78 | +165.49% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $42.30 | -12.53% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $176 → $147 | $131.16 | +12.08% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $46.69 | +39.22% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $7.43 | -46.16% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.12 | -1.19% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $23.97 | +25.16% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $18.69 | -30.44% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $90.43 | -24.80% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.65 | -54.89% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.04 | +90.56% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.92 | +993.75% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $138.15 | -18.20% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $31.43 | +33.63% | 3 | Oct 16, 2023 |
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $6.04
Upside: +32.45%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $219.16
Upside: +31.87%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $31.34
Upside: +30.82%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $11.37
Upside: +14.34%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $152.37
Upside: +17.48%
Alkermes
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $32.89
Upside: +36.82%
Supernus Pharmaceuticals
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $46.02
Upside: +41.24%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $320.20
Upside: +6.81%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $155.51
Upside: -24.12%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $24.03
Upside: +4.04%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $73.72
Upside: +64.13%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.78
Upside: +165.49%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $42.30
Upside: -12.53%
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $131.16
Upside: +12.08%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.69
Upside: +39.22%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $7.43
Upside: -46.16%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.12
Upside: -1.19%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $23.97
Upside: +25.16%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $18.69
Upside: -30.44%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $90.43
Upside: -24.80%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.65
Upside: -54.89%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.04
Upside: +90.56%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.92
Upside: +993.75%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $138.15
Upside: -18.20%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $31.43
Upside: +33.63%